Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
India
/
Pharmaceuticals & Biotech
Create a narrative
Hikal Community
BSE:524735 Community
1
Narratives
written by author
0
Comments
on narratives written by author
2
Fair Values set
on narratives written by author
Community Investing Ideas
Hikal
Popular
Undervalued
Overvalued
Hikal
AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst
Global Supply Chain Diversification Will Unlock Indian CRAMS Potential
Key Takeaways Strengthened regulatory compliance and successful audits position Hikal as a preferred global supplier, supporting sustainable margin expansion and stable long-term revenues. Focused R&D, capacity expansion, and diversification into specialty segments drive recurring contracts, reduce risk, and enhance earnings stability.
View narrative
₹390.00
FV
33.9% undervalued
intrinsic discount
8.98%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
5 days ago
author updated this narrative
Your Valuation for
524735
524735
Hikal
Your Fair Value
₹
Current Price
₹257.65
14.3% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
0
29b
2015
2018
2021
2024
2025
2027
2030
Revenue ₹28.8b
Earnings ₹994.4m
Advanced
Set Fair Value